samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > dendritic cells for cancer immunotherapy
PUBLICATIONS
European Biopharmaceutical Review

Dendritic Cells for Cancer Immunotherapy

Cancer is one of the major killers in the developed world, accounting for over one million deaths in North America and Europe annually. In the US, the annual incidence of cancer is approximately 1,200,000, and the number of people dying of the disease each year is about 500,000 (1). The American Cancer Society estimates that one in three Americans will develop cancer in his or her lifetime. Between 1970 and 1990, the overall five-year survival rate of treated cancer patients improved by about 10 per cent as a result of earlier detection, improved radio- and chemotherapies and, possibly, changes in living habits. However, with the exception of small cell lung carcinoma and breast cancer, improvement in advanced stages has been negligible. Moreover, the lack of specificity of radio- and chemotherapies causes severe side effects. Therefore, new therapies with better efficacy and specificity are needed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jean-Pierre Abastado, Vice-President, Scientific Affairs, IDM

Jean-Pierre Abastado is Vice-President in charge of Scientific Affairs at IDM. He is on leave from the CNRS, where he is Research Director. He graduated from the Ecole Polytechnique in 1978 and obtained his PhD in biological sciences from the University of Paris VI in 1986. From 1979 to 1998, he held several positions at the Pasteur Institute (in Paris, France) and NIH (in Bethesda, US). From 1990 to 1998, he managed a group of eight people in the unit of Professor Philippe Kourilsky, specialising in molecular biology and fundamental immunology. Between 1994 and 1998 he was named, on several occasions, an independent expert by the Pasteur Institute, Pasteur-Mérieux Sérums et Vaccins and INSERM. He is the Author of more than 80 scientific publications and of several patent applications in France and the US.

spacer
Jean-Pierre Abastado
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Team Consulting expands facilities to meet client demand

To meet growing client demand, Team Consulting, a medical device design and development consultancy based in Ickleton, Cambridge, has expanded its facilities to now offer over 5,500 sq ft of lab spaces. Based in the picturesque 13th century Abbey Barns site, the company’s expansion sees the addition of a whole new building with several high-spec lab spaces, design facilities and collaborative workspaces.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement